|
Mountain View, California, October 23, 2003/PRNewswire/ – SurroMed, Inc.
today announced that it has been awarded an SBIR grant from the National Institutes of Health entitled “Prolonging Annexin Antithrombotic Activity.” SurroMed is undertaking development of a modified version of recombinant human annexin V, a naturally occurring protein, for multiple cardiovascular indications.
“Annexin can prevent thrombosis without increasing hemorrhage, and we are undertaking preclinical analysis of modified annexin designed to significantly improve anticoagulant activity,” said Anthony C. Allison, D. Phil., B.M., B.Ch., SurroMed Distinguished Scientist.
“Annexin is our first therapeutic program, and this grant will complement the in vitro development work undertaken at SurroMed and the preclinical work being performed for SurroMed at various academic institutions,” said Gordon Ringold, Ph.D., Chairman and CEO of SurroMed.
The SBIR program is designed to support small businesses conducting innovative research focused on the commercialization of novel technologies. Innovation and the potential for commercialization are among the important criteria used by the NIH in its scientific and technical merit evaluation process.
About SurroMed, Inc. - The Biomarker Company
SurroMed is pioneering biomarker enabled drug discovery and development. The company
focuses on discovering and applying biomarkers to improve the drug discovery and
development process and enable the precise diagnosis and personalized treatment of
disease. SurroMed's research process yields biological markers and information that
enable accelerated, cost-efficient discovery and development of new therapeutic products,
as well as development of diagnostic tests for early disease detection, disease staging,
patient stratification, and guiding and monitoring therapy.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Ian McConnell, Ph.D
Senior Account Executive
(415) 677-4455 ext. 233
email: [email protected]
|